GUIDED THERAPEUTICS INC 8-K

What Happened
Guided Therapeutics, Inc. announced it completed a warrant exchange on March 2, 2026. The company accepted and cancelled 4,825,000 Eligible Warrants (about 22.7% of the outstanding eligible warrants) and issued 4,825,000 shares of restricted common stock in exchange. The company received aggregate cash proceeds of $980,000 from exercises related to the exchange.

Key Details

• 4,825,000 Eligible Warrants were validly tendered and accepted (22.7% of eligible warrants) and then cancelled upon issuance of shares.
• The company issued 4,825,000 restricted shares of common stock on March 2, 2026. Outstanding common shares increased from 86,691,976 to 91,516,976.
• Cash proceeds from the exchange totaled $980,000. Under the offer, $0.65 warrants could be exercised at $0.25 and $0.50 warrants at $0.20 if exercised by the Feb 25, 2026 expiration.
• After the exchange, 16,398,080 Eligible Warrants remain outstanding: 11,973,080 expire between Sept 1 and Oct 18, 2026, and 4,425,000 expire between Sept 1 and Oct 18, 2027. Participants in the exchange had the expiration date of any remaining unexercised Eligible Warrants extended by one year from their original expiration.

Why It Matters
This transaction reduced the company’s warrant overhang by roughly 22.7% while raising nearly $1.0 million in cash and increasing the share count by about 5.6 million shares. For investors, that means some dilution to existing shareholders (increase in shares outstanding) but also a modest cash infusion and fewer outstanding warrants that could otherwise add future dilution. The remaining substantial warrant pool and upcoming 2026 expirations remain relevant for future dilution and potential cash inflows if exercised.